Protara Therapeutics, Inc. Adjustments to Additional Paid in Capital, Other
Protara Therapeutics, Inc. (TARA) reported Adjustments to Additional Paid in Capital, Other of $6.36 million for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-11.
Discontinued › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalOther · last filed 2021-03-11
- Protara Therapeutics, Inc. adjustments to additional paid in capital, other for the quarter ending 2020-12-31 was $1.31M.
- Protara Therapeutics, Inc. adjustments to additional paid in capital, other for the quarter ending 2020-09-30 was $1.31M, a 5709.66% increase year-over-year.
- Protara Therapeutics, Inc. adjustments to additional paid in capital, other for the quarter ending 2020-06-30 was $1.31M, a 5742.97% increase year-over-year.
- Protara Therapeutics, Inc. adjustments to additional paid in capital, other for the quarter ending 2020-03-31 was $2.43M, a 10698.54% increase year-over-year.
- Protara Therapeutics, Inc. adjustments to additional paid in capital, other for fiscal 2020 was $6.36M, a 17558.33% increase from fiscal 2019.
- Protara Therapeutics, Inc. adjustments to additional paid in capital, other for fiscal 2019 was $36.00K.
- Protara Therapeutics, Inc. adjustments to additional paid in capital, other for fiscal 2014 was $1.43M.
| Period end | Adjustments to Additional Paid in Capital, Other 3 month | Adjustments to Additional Paid in Capital, Other 6 month | Adjustments to Additional Paid in Capital, Other 9 month | Adjustments to Additional Paid in Capital, Other 12 month |
|---|---|---|---|---|
| 2020-12-31 | $1.31M derived: 10-K 12 month − 3 quarters · filed 2021-03-11 | $2.61M derived: sum of 2 quarters · filed 2021-03-11 | $3.93M derived: sum of 3 quarters · filed 2021-03-11 | $6.36M 10-K · filed 2021-03-11 |
| 2020-09-30 | $1.31M 10-Q · filed 2020-11-12 | $2.62M derived: sum of 2 quarters · filed 2020-11-12 | $5.05M derived: sum of 3 quarters · filed 2020-11-12 | |
| 2020-06-30 | $1.31M 10-Q · filed 2020-11-12 | $3.74M derived: sum of 2 quarters · filed 2020-11-12 | ||
| 2020-03-31 | $2.43M 10-Q · filed 2020-11-12 | |||
| 2019-12-31 | $36.00K 10-K · filed 2021-03-11 | |||
| 2019-09-30 | $22.50K 10-Q · filed 2020-11-12 | $45.00K derived: sum of 2 quarters · filed 2020-11-12 | $67.50K derived: sum of 3 quarters · filed 2020-11-12 | |
| 2019-06-30 | $22.50K 10-Q · filed 2020-11-12 | $45.00K derived: sum of 2 quarters · filed 2020-11-12 | ||
| 2019-03-31 | $22.50K 10-Q · filed 2020-11-12 | |||
| 2014-12-31 | $1.43M 10-K · filed 2017-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |